Zobrazeno 1 - 10
of 10
pro vyhledávání: '"May Montellano"'
Autor:
Myew-Ling Toh, Celine Zocchetti, Jaime Santos, Rontgene Solante, Stephanie Meyer, Cesar Mascareñas, Nicole Perreras, Claire Vigne, May Montellano
Publikováno v:
Pediatric Infectious Disease Journal. 40:856-863
Background Incorporating dengue vaccination into existing childhood vaccination programs could increase vaccine coverage. This study assessed the safety and immunogenicity of concomitant versus sequential administration of the combined tetanus toxoid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24b943a615889197434cf833154bd3d5
https://doi.org/10.1097/inf.0000000000003220
https://doi.org/10.1097/inf.0000000000003220
Autor:
Jasur, Danier, Luis, Rivera, Carine, Claeys, Ghassan, Dbaibo, Varsha K, Jain, Pope, Kosalaraksa, Wayne, Woo, Emad, Yanni, Khalequ, Zaman, Beatriz, Acosta, Arshad, Amanullah, Miguel, Ariza, Maria, Luisa Arroba Basanta, Ashish, Bavdekar, Alfonso, Carmona, Luis, Cousin, Adolfo, Diaz, Javier, Diez-Domingo, Ener, Cagri Dinleyici, Saul N, Faust, Jose, Garcia-Sicilia, Grace D, Gomez-Go, Liza, Antionette Gonzales, Mustafa, Hacimustafaoglu, Stephen M, Hughes, Allen, Izu, Teresa, Jackowska, Shashi, Kant, Marilla, Lucero, Josep, Mares Bermudez, Federico, Martinón-Torres, May, Montellano, Roman, Prymula, Thanyawee, Puthanakit, Renata, Ruzkova, Iwona, Sadowska-Krawczenko, Jyoti, Soni, Henryk, Szymanski, Angels, Ulied, Anne, Schuind, Bruce L, Innis, K, Zaman
Publikováno v:
PEDIATRIC INFECTIOUS DISEASE JOURNAL
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Background: In an exploratory analysis of an inactivated quadrivalent influenza vaccine (IIV4) trial in children 6-35 months without risk factors for influenza, we evaluated clinical presentation of influenza illness and vaccine impact on health outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534b4cea06f21bc5f4f84e067e5b264d
https://doi.org/10.1097/inf.0000000000002387
https://doi.org/10.1097/inf.0000000000002387
Autor:
Mustafa Hacimustafaoglu, José Garcia-Sicilia, Alfonso Carmona, Angels Ulied, Bruce L. Innis, Khalequ Zaman, Emad Yanni, Wayne Woo, Marilla G. Lucero, May Montellano, Jyoti Soni, Thanyawee Puthanakit, Luis Rivera, Pope Kosalaraksa, Maria L. A. Gonzales, Roman Prymula, Federico Martinón-Torres, Ghassan Dbaibo, Luis Cousin, Ener Cagri Dinleyici, Renata Ruzkova, Javier Díez-Domingo, Anne Schuind, Jasur Danier, Teresa Jackowska, Maria L. Arroba Basanta, Allen Izu, Beatriz Acosta, Iwona Sadowska-Krawczenko, Varsha K. Jain, Stephen M. Hughes, Ashish Bavdekar, Carine Claeys, Henryk Szymański, Josep Mares Bermudez, Saul N. Faust, Miguel Ariza, Shashi Kant, Arshad Amanullah, Grace D. Gomez-Go, Adolfo Diaz
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6–35 months of age in a phase III, observer-blind trial. Methods: The aim of this analysis was to
Background: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6–35 months of age in a phase III, observer-blind trial. Methods: The aim of this analysis was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10d8ab0201f8729a837b43fd82126b21
https://pubmed.ncbi.nlm.nih.gov/31725115
https://pubmed.ncbi.nlm.nih.gov/31725115
Autor:
Charissa Fay Corazon B. Tabora, Birgit Thierry-Carstensen, Lulu Bravo, Josefina Carlos, Mie Vestergaard Kusk, Ananda S Bandyopadhyay, Salvacion R. Gatchalian, Charlotte Sørensen, Pernille Ingemann Nielsen, May Montellano, Henrik Wachmann, Pernille N. Tingskov
Publikováno v:
Vaccine
Background A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and the cost constraints of IPV. The objective of this trial was to demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692db1b072cbbba0675865bc755729a4
https://pubmed.ncbi.nlm.nih.gov/31703934
https://pubmed.ncbi.nlm.nih.gov/31703934
Autor:
Iris De Bruijn, Javier Díez-Domingo, Stephanie Pepin, Sanjay Gurunathan, Marie Pierre Kazek-Duret, Celia Diaz Gonzalez, Federico Martinón-Torres, Efimia Papadopoulou-Alataki, Doris Maribel Rivera-Medina, Martin Dupuy, Clare Cutland, Jo-Anne A. de Castro, Maria Theodoriadou, May Montellano, Lulu Bravo, Miguel Ariza, Jaime Santos, Charissa Borja-Tabora
Publikováno v:
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
instname
Background A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetra™, Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf320617fa433255aea55bf2cc6bb33
https://pubmed.ncbi.nlm.nih.gov/30558818
https://pubmed.ncbi.nlm.nih.gov/30558818
Autor:
Carine Claeys, Khalequ Zaman, Ghassan Dbaibo, Ping Li, Allen Izu, Pope Kosalaraksa, Luis Rivera, Beatriz Acosta, Maria Luisa Arroba Basanta, Asma Aziz, Miguel Angel Cabanero, Vijayalakshmi Chandrashekaran, Bartholomew Corsaro, Luis Cousin, Adolfo Diaz, Javier Diez-Domingo, Ener Cagri Dinleyici, Saul N Faust, Damien Friel, Jose Garcia-Sicilia, Grace D Gomez-Go, Maria Liza Antoinette Gonzales, Stephen M Hughes, Teresa Jackowska, Shashi Kant, Marilla Lucero, Ludovic Malvaux, Josep Mares Bermudez, Federico Martinon-Torres, Mariano Miranda, May Montellano, Maria Amor Peix Sambola, Roman Prymula, Thanyawee Puthanakit, Renata Ruzkova, Iwona Sadowska-Krawczenko, Ignacio Salamanca de la Cueva, Etienne Sokal, Jyoti Soni, Henryk Szymanski, Angels Ulied, Anne Schuind, Varsha K Jain, Bruce L Innis, Beatriz Acostas, Arshad Amanullah, Miguel Ariza, Milagros Bautista, Ashish Bavdekar, Bhavesh Bodalia, Lulu C Bravo, Jerzy Brzostek, Ian Caldwell, Alfonso Carmona, Jasur Danier, Ana Isabel Diaz Cirujano, Martine Docx, Daniel Drazan, Andrzej Galaj, Fermin Garcia Rodriguez, Trevor Gooding, Mustafa Hacimustafaoglu, Paul Heath, Paul Heaton, Sanjay Lalwani, Jennifer Langlands, Karl Logghe, Jolanta Mantyka, Damien McNally, Edyta Miszczak-Kowalska, Simon Royal, Benjamin Sablan, Matthew Snape, Richard Tomlinson, Marc Verghote, Andre Vertruyen, Marie Wheeler
Publikováno v:
LANCET CHILD & ADOLESCENT HEALTH
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
BackgroundDespite the importance of vaccinating children younger than 5 years, few studies evaluating vaccine prevention of influenza have been reported in this age group. We evaluated efficacy of an inactivated quadrivalent influenza vaccine (IIV4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b340ce6383216acb8bc04f9d8ea904
https://pubmed.ncbi.nlm.nih.gov/30169261
https://pubmed.ncbi.nlm.nih.gov/30169261
Autor:
Thomas Breuer, Pio Lopez, Lily Yin Weckx, Gary Dubin, Idis Faingezicht, Miguel Angel Rodriguez Weber, Rolando Ulloa-Gutierrez, Bruce L. Innis, Eduardo Lazcano-Ponce, Serge Durviaux, Aurelio Cruz-Valdez, David W. Vaughn, Abiel Mascareñas de los Santos, Terry Nolan, Fong Seng Lim, Pensri Kosuwon, May Montellano, Louis Fries, Angkool Kerdpanich, Marco Aurélio Palazzi Sáfadi, Juan Carlos Tinoco, Sandra Litao, Charissa Borja-Tabora, Sumita Roy-Ghanta, Marcela Hernandez-de Mezerville, Ping Li
Publikováno v:
Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
The Journal of Infectious Diseases
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
The Journal of Infectious Diseases
GlaxoSmithKline Biologicals Background. the vaccine efficacy (VE) of 1 or 2 doses of AS03-adjuvanted influenza A(H1N1) vaccine relative to that of 2 doses of nonadjuvanted influenza A(H1N1) vaccine in children 6 months to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d631b1be0a1ed5db8e948a4cb23910a
https://doi.org/10.1093/infdis/jiu173
https://doi.org/10.1093/infdis/jiu173
Publikováno v:
Infectious Diseases in Clinical Practice. 19:326-331
This article reviews the arguments for a hepatitis B vaccination schedule at birth and at 1 month and 6 months of age. Vertical transmission is a major route of hepatitis B infection and in 2009 the World Health Organization stated that "All infants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::987bfc502caecfedc1d4fdab3bfc2bfc
https://doi.org/10.1097/ipc.0b013e31822b7dda
https://doi.org/10.1097/ipc.0b013e31822b7dda
Autor:
Wolfgang Jilg, Veerachai Watanveerade, Tino F. Schwarz, Ping Li, May Montellano, Gérard Zalcman, Serge Fitoussi, David W. Vaughn, Angkool Kerdpanich, Odile Launay, Xavier Duval, Vinod Bambure, Paul Gillard, Adrian Caplanusi, Anuradha Madan, Jürgen J. Wenzel
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, BioMed Central, 2013, 13 (1), pp.435. ⟨10.1186/1471-2334-13-435⟩
BMC Infectious Diseases, BioMed Central, 2013, 13 (1), pp.435. ⟨10.1186/1471-2334-13-435⟩
Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/Californ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8267ecf34b2938ffe505d0a3ad5bf45e
https://www.hal.inserm.fr/inserm-00868824
https://www.hal.inserm.fr/inserm-00868824
Autor:
Valsan Philip Verghese, Anand Prakash Dubey, Marie Van der Wielen, Veronique Bianco, Salvacion Gatchalian, Ghassan Dbaibo, Hemant Jain, Jacqueline M. Miller, Ziad A. Memish, May Montellano
Publikováno v:
The Pediatric infectious disease journal. 30(4)
Meningococcal disease remains an important cause of invasive bacterial infections in children less than 5 years of age. Immunogenicity and safety of the investigational ACWY vaccine conjugated with tetanus toxoid (ACWY-TT, GlaxoSmithKline Biologicals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b834d9dde62bb519a259ccd0fe31edb3
https://pubmed.ncbi.nlm.nih.gov/21278617
https://pubmed.ncbi.nlm.nih.gov/21278617